Glibenclamide (INN), also known as glyburide (USAN), is an anti-diabetic drug in a class of medications known as sulfonylureas, used in the treatment of type II diabetes. The drug works by inhibiting ATP-sensitive potassium channels in pancreatic beta cells. This inhibition causes cell membrane depolarization, opening of voltage-dependent calcium channels, thus triggering an increase in intracellular calcium into the beta cell which stimulates insulin release. It is sold in doses of 1.25mg, 2.5mg and 5mg, under the trade names Diabeta®, Glynase® and Micronase® in the United States and Daonil®, Semi-Daonil® and Euglucon® in the United Kingdom.
It is also sold in combination with metformin under the trade name Glucovance®.
The drug is contraindicated in pregnant women. It is also a major cause of drug induced hypoglycaemia.
More on [ Glibenclamide ]

DrugDigest: Glyburide ( Glucovance ) - Information on dosage, usage, side effects, interactions, and drug comparisons including generics when available.
Glucovance - Glyburide and metformin. New oral medication for the treatment of type 2 diabetes.
Meta Description: [ Bristol-Myers Squibb is a global pharmaceutical company whose mission is to extend and enhance human life by developing innovative medicines and health care products. ]
| Increased Risk of Bone Fractures in Women Treated with Diabe | |